Stock AnalizKestra Medical Technologies, Ltd. KMTS
Medical/Dental Instruments · IPO 2025 · data as of November 13, 2026
Kestra Medical Technologies, Ltd. (KMTS) is a healthcare company listed in the US with a market value of about $1.7B. In the twelve months to July 31, 2026 it had revenue of $107M and net income of -$150M, a net margin of -140.4%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -34%.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2026 | 2025 | 2024 |
|---|---|---|---|---|
| Revenue | $107M | $95M | $60M | $28M |
| Net income | -$150M | -$132M | -$114M | -$94M |
| Free cash flow | -$123M | -$117M | -$101M | -$84M |
| EPS (diluted) | $-2.67 | $-2.43 | $-5.13 | $-5.07 |
| Net margin | -140.4% | -138.4% | -190.3% | -338.4% |
| ROIC | — | -34.7% | -33.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $31.12, 9% above the current price; targets range from $28.00 to $34.00; the consensus rating is “Strong buy”; expected EPS is $-2.45 for the fiscal year ending April 30, 2027.
Frequently asked questions
Does Kestra Medical Technologies pay a dividend?
Not currently.
Is Kestra Medical Technologies a good stock to buy?
We do not give buy or sell advice. Kestra Medical Technologies scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.